CVRx Names John Landry CFO as Shares Close at 2.97

CVRx, Inc. (CVRX) said on Monday that John Landry will become chief financial officer effective October 12, succeeding John Oasheim, who stays on through a transition period; CVRX last traded at 2.97, down 2.30% on the day.

CVRx, Inc. (CVRX) told investors on Monday that John Landry will take over as chief financial officer effective October 12. He succeeds John Oasheim, who is to remain with the company for a transition period, according to the announcement carried by Nasdaq Markets.

That is the whole of the disclosed fact set, and it is worth being precise about what it does and does not say. CVRx did not announce a change to guidance, a restatement, a financing, or a strategic review alongside the appointment. It announced a scheduled handover with an overlap period. For a commercial-stage medical device company — one selling a product rather than waiting on a pivotal trial readout — that is the least disruptive shape a CFO change can take.

A dated handover, not an abrupt exit

The structure matters more than most investors give it credit for. An effective date roughly three weeks out, plus a predecessor who stays on to hand over, is the signature of a planned succession. It is the opposite of the pattern that unsettles small-cap shareholders: a finance chief leaving immediately, no named successor, an interim appointed from the controller's office, and no explanation.

Transition periods also serve a mundane but consequential purpose. Quarter-end close, audit coordination, revenue recognition policy on device sales, and reimbursement-related accounting all sit with the CFO's office. Having the outgoing officer available while the incoming one learns the reporting calendar reduces the risk of a late filing or a control weakness disclosure — the kind of housekeeping failure that costs a small-cap company more in credibility than in cash.

CVRx did not disclose Landry's prior roles in the announcement as summarized, and no compensation terms were stated. Investors looking for that detail will find it in the company's subsequent filings rather than in the initial release.

What the market did with the news

The reaction was muted to mildly negative, and it came on a strong tape. CVRX last traded at 2.97, down 2.30% from the prior close of 3.04, with a session range of 2.91 to 3.06, as of the last trade at 20:00 GMT on Monday, September 22. The market is closed; that is the most recent print, not a live quote.

The context makes the small decline stand out a little more than it otherwise would. Broad equity benchmarks were firmly higher in the same session. SPY, the exchange-traded fund tracking the S&P 500, closed at $773.50, up 1.55% from $761.69. QQQ, tracking the Nasdaq 100, closed at $741.47, up 2.77% from $721.45 — a large single-day move for a mega-cap index proxy. DIA, tracking the Dow 30, closed at $519.78, up 0.76%.

So CVRX finished lower while the three headline U.S. equity proxies finished higher, with the Nasdaq 100 tracker posting the strongest gain of the three. That is a divergence, but it should not be over-read. At a share price under three units of currency, a stock moves on small absolute changes, and the intraday range shows the print crossed above the prior close at one point before settling below it. Single-session moves in micro-priced equities are noise more often than signal, particularly when the news itself carries no financial content.

Why the CFO seat carries extra weight at a commercial-stage device maker

"Commercial-stage" is the phrase to focus on. It means the company is selling into the market rather than funding a pipeline toward an eventual approval. That shifts what the finance function actually does day to day.

For a pre-revenue developer, the CFO is principally a capital-markets officer: raise money, manage runway, communicate milestones. For a company with product in the field, the job broadens considerably:

• Unit economics. Gross margin per device, cost of goods as manufacturing scales, and whether contribution margin improves with volume.
• Sales-force productivity. How much revenue each territory and each rep generates, and how long a new hire takes to pay for themselves.
• Reimbursement and coding. Whether payers cover the procedure, at what rate, and how quickly claims convert to cash.
• Cash conversion. Inventory held at hospitals, receivables from institutional buyers, and the working-capital drag that comes with growth.
• Funding the ramp. Whether the path to self-funding operations is close enough to avoid dilutive equity issuance.

Those are the levers a new finance chief inherits, and they are where a change in approach would eventually show up — in disclosure detail, in how guidance is framed, in whether the company starts publishing operating metrics it had previously kept general.

What to watch after October 12

The first meaningful test is the first quarterly call with Landry in the seat. Three things are worth listening for.

First, continuity of guidance philosophy. New CFOs sometimes reset expectations early, on the reasonable logic that a conservative first quarter is easier to beat than an inherited forecast is to defend. Whether CVRx maintains, refines, or reframes its outlook will say more about the transition than the appointment itself did.

Second, the disclosure package. Additions to the metrics a company reports — revenue by geography, implant or procedure counts, sales-territory headcount — often follow a finance leadership change, because a new CFO gets one free opportunity to change what the company talks about.

Third, the balance sheet posture. Any commercial-stage device company still scaling has to answer how the ramp is funded. A shift in tone on financing, whether toward debt, an at-the-market facility, or a stated intention to avoid raising, is a signal in its own right.

Beyond that, watch for follow-on filings covering the employment terms and for how long Oasheim's transition period actually runs. A handover measured in weeks reads differently from one measured in a quarter or more, and the company has said only that it is consistent with the arrangements in place.

For now the appointment is what it appears to be: an orderly change at the top of the finance function, disclosed ahead of the effective date, with the outgoing officer still on hand. The share-price consequence, on the evidence of Monday's close, was minimal.

Key facts

• Incoming CFO: John Landry, effective October 12
• Predecessor: John Oasheim, staying for a transition period
• Share price: CVRX last traded at 2.97, -2.30%, as of 20:00 GMT Sept. 22, 2026
• Session range: 2.91–3.06; prior close 3.04

Frequently asked questions

Who is CVRx's new chief financial officer?

CVRx, Inc. said on Monday that John Landry will serve as chief financial officer, with the appointment effective October 12. He succeeds John Oasheim in the role. The company's announcement did not disclose compensation terms or a detailed biography; those details would typically appear in subsequent regulatory filings rather than the initial release.

What happens to the outgoing CFO?

John Oasheim will remain with CVRx for a transition period, the company said. Overlapping the outgoing and incoming finance chiefs is standard practice: it keeps institutional knowledge available through quarter-end close, audit coordination and reporting-calendar handover, reducing the risk of filing delays or internal-control problems during the changeover.

How did CVRX shares react to the announcement?

CVRX last traded at 2.97, down 2.30% from a prior close of 3.04, with a session range of 2.91 to 3.06, as of the last trade at 20:00 GMT on Monday, September 22, 2026. The market is now closed, so that figure is the most recent print rather than a live quote.

Did the broader market move in the same direction?

No. Major benchmark proxies closed higher in the same session. SPY, tracking the S&P 500, ended at $773.50, up 1.55%. QQQ, tracking the Nasdaq 100, closed at $741.47, up 2.77%. DIA, tracking the Dow 30, finished at $519.78, up 0.76%. CVRX finished lower against that stronger tape.

What does 'commercial-stage medical device company' mean?

It means the company is already selling a product into the market rather than funding development toward a future regulatory approval. That changes the finance function's priorities: gross margin per unit, sales-force productivity, insurance reimbursement, inventory and receivables management, and funding the commercial ramp all move to the centre of the CFO's job.

What should investors watch next?

The first quarterly call with Landry in the role is the key event. Three things matter: whether guidance is maintained or reframed, whether the company adds new operating metrics to its disclosure, and any change in tone on how the commercial ramp will be funded. Subsequent filings should also detail employment terms.

Sources

• CVRx Appoints As John Landry CFO — Nasdaq Markets